Nucleic Acid Based Gene Therapy Market Report 2026

Nucleic Acid Based Gene Therapy Market Overview

• Nucleic Acid Based Gene Therapy market size has reached to $0.88 billion in 2025 • Expected to grow to $1.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: Rising Financial Support by Governments and Companies Accelerating Gene Therapy Development • Market Trend: Personalized Autologous Stem Cell Therapies Driving Growth in Rare Disease Treatment • North America was the largest region in 2025 and Western Europe is the fastest growing region.

What Is Covered Under Nucleic Acid Based Gene Therapy Market?

Nucleic acid-based gene therapy is a medical treatment approach that uses nucleic acids (such as DNA or RNA) to modify or manipulate genes within a patient's cells to treat or prevent diseases. This therapy aims to address the root cause of a disease at the genetic level by directly intervening in the genetic material that leads to the malfunctioning of cells. The main technologies in nucleic acid-based gene therapy are anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogues, ribozymes, aptamers, and others. The nucleoside analogues are a significant class of antiviral agents that are generally utilized in the therapy of human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV). The various applications include oncology, muscular dystrophy, muscular disorders, and rare diseases that are used by end-users such as hospitals and clinics and academic and research institutes.

What Is The Nucleic Acid Based Gene Therapy Market Growth Forecast?

The nucleic acid based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing adoption of crispr-based treatments, rising demand for rare disease therapies, expansion of gene therapy manufacturing facilities, growing focus on personalized oncology treatments, increasing public and private funding for genetic medicine. Major trends in the forecast period include increasing adoption of rna-based therapeutics, rising use of viral and non-viral gene delivery systems, growing focus on targeted gene editing technologies, expansion of personalized genetic therapies, enhanced emphasis on precision medicine applications.

Global Nucleic Acid Based Gene Therapy Market Segmentation

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies 2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases 3) By End User: Hospitals And Clinics, Academic And Research Institutes Subsegments: 1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO) 2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies 3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun) 4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs 5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes 6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers 7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

What Is The Driver Of The Nucleic Acid Based Gene Therapy Market?

The rising financial support by governments and companies is expected to propel the growth of the nucleic acid based gene therapy market going forward. Financial support refers to monetary investments, grants, or subsidies provided by public or private institutions to advance research, development, and commercialization of therapies. The rising financial support is due to increasing global prioritization of treatments for rare and genetic diseases that currently lack effective cures. Government funding in nucleic-acid–based gene therapy accelerates progress by supplying the essential resources for research, clinical trials, and infrastructure that directly drive innovation and translation into effective treatments. For instance, in July 2023, according to the U.S. National Institutes of Health, a U.S.-based federal health research agency, over $140 million was awarded to accelerate genome editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders, marking a significant increase compared to prior annual funding of $92 million in 2022. Therefore, the rising financial support by governments and companies is driving the growth of the nucleic acid based gene therapy industry.

Key Players In The Global Nucleic Acid Based Gene Therapy Market

Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Global Nucleic Acid Based Gene Therapy Market Trends and Insights

Major companies operating in the nucleic acidbased gene therapy market are focusing on personalized, autologous stem-cell therapies, such as genetically modified hematopoietic stem-cell infusions, to treat rare inherited diseases. Autologous therapies refer to treatments in which a patient’s own stem cells are removed, genetically corrected and re-infused to restore the missing biochemical function. For instance, in March 2024, Orchard Therapeutics, a US-based company that offers pharmaceuticals announced Lenmeldy (atidarsagene autotemcel) approved by the U.S. Food and Drug Administration for children with metachromatic leukodystrophy (MLD). Lenmeldy uses the patient’s own hematopoietic stem cells that have been genetically modified to express a functional ARSA gene, enabling enzyme restoration in the nervous system. This regulatory success underscores how companies can commercialize complex, autologous gene therapies despite high manufacturing costs.

What Are Latest Mergers And Acquisitions In The Nucleic Acid Based Gene Therapy Market?

In March 2023, Moderna, Inc., a US-based biotechnology company partnered with Generation Bio. With this partnership, Moderna Inc. aims to develop novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines and fund all research and development activities associated with this collaboration, including a pre-payment for research efforts. Generation Bio is a US-based biotechnology company that provides nucleic acid based gene therapy.

Regional Outlook

North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

What Defines the Nucleic Acid Based Gene Therapy Market?

The nucleic acid based gene therapy market consists of sales of nucleic acid based gene therapy technologies such as anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers, and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.